Cargando…
Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma
BACKGROUND: The genetic origins of chemotherapy resistance are well established; however, the role of epigenetics in drug resistance is less well understood. To investigate mechanisms of drug resistance, we performed systematic genetic, epigenetic, and transcriptomic analyses of an alkylating agent-...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857420/ https://www.ncbi.nlm.nih.gov/pubmed/27146673 http://dx.doi.org/10.1186/s13073-016-0305-0 |
_version_ | 1782430656407535616 |
---|---|
author | Flinders, Colin Lam, Larry Rubbi, Liudmilla Ferrari, Roberto Fitz-Gibbon, Sorel Chen, Pao-Yang Thompson, Michael Christofk, Heather B Agus, David Ruderman, Daniel Mallick, Parag Pellegrini, Matteo |
author_facet | Flinders, Colin Lam, Larry Rubbi, Liudmilla Ferrari, Roberto Fitz-Gibbon, Sorel Chen, Pao-Yang Thompson, Michael Christofk, Heather B Agus, David Ruderman, Daniel Mallick, Parag Pellegrini, Matteo |
author_sort | Flinders, Colin |
collection | PubMed |
description | BACKGROUND: The genetic origins of chemotherapy resistance are well established; however, the role of epigenetics in drug resistance is less well understood. To investigate mechanisms of drug resistance, we performed systematic genetic, epigenetic, and transcriptomic analyses of an alkylating agent-sensitive murine lymphoma cell line and a series of resistant lines derived by drug dose escalation. METHODS: Dose escalation of the alkylating agent mafosfamide was used to create a series of increasingly drug-resistant mouse Burkitt’s lymphoma cell lines. Whole genome sequencing, DNA microarrays, reduced representation bisulfite sequencing, and chromatin immunoprecipitation sequencing were used to identify alterations in DNA sequence, mRNA expression, CpG methylation, and H3K27me3 occupancy, respectively, that were associated with increased resistance. RESULTS: Our data suggest that acquired resistance cannot be explained by genetic alterations. Based on integration of transcriptional profiles with transcription factor binding data, we hypothesize that resistance is driven by epigenetic plasticity. We observed that the resistant cells had H3K27me3 and DNA methylation profiles distinct from those of the parental lines. Moreover, we observed DNA methylation changes in the promoters of genes regulated by E2a and members of the polycomb repressor complex 2 (PRC2) and differentially expressed genes were enriched for targets of E2a. The integrative analysis considering H3K27me3 further supported a role for PRC2 in mediating resistance. By integrating our results with data from the Immunological Genome Project (Immgen.org), we showed that these transcriptional changes track the B-cell maturation axis. CONCLUSIONS: Our data suggest a novel mechanism of drug resistance in which E2a and PRC2 drive changes in the B-cell epigenome; these alterations attenuate alkylating agent treatment-induced apoptosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-016-0305-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4857420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48574202016-05-06 Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma Flinders, Colin Lam, Larry Rubbi, Liudmilla Ferrari, Roberto Fitz-Gibbon, Sorel Chen, Pao-Yang Thompson, Michael Christofk, Heather B Agus, David Ruderman, Daniel Mallick, Parag Pellegrini, Matteo Genome Med Research BACKGROUND: The genetic origins of chemotherapy resistance are well established; however, the role of epigenetics in drug resistance is less well understood. To investigate mechanisms of drug resistance, we performed systematic genetic, epigenetic, and transcriptomic analyses of an alkylating agent-sensitive murine lymphoma cell line and a series of resistant lines derived by drug dose escalation. METHODS: Dose escalation of the alkylating agent mafosfamide was used to create a series of increasingly drug-resistant mouse Burkitt’s lymphoma cell lines. Whole genome sequencing, DNA microarrays, reduced representation bisulfite sequencing, and chromatin immunoprecipitation sequencing were used to identify alterations in DNA sequence, mRNA expression, CpG methylation, and H3K27me3 occupancy, respectively, that were associated with increased resistance. RESULTS: Our data suggest that acquired resistance cannot be explained by genetic alterations. Based on integration of transcriptional profiles with transcription factor binding data, we hypothesize that resistance is driven by epigenetic plasticity. We observed that the resistant cells had H3K27me3 and DNA methylation profiles distinct from those of the parental lines. Moreover, we observed DNA methylation changes in the promoters of genes regulated by E2a and members of the polycomb repressor complex 2 (PRC2) and differentially expressed genes were enriched for targets of E2a. The integrative analysis considering H3K27me3 further supported a role for PRC2 in mediating resistance. By integrating our results with data from the Immunological Genome Project (Immgen.org), we showed that these transcriptional changes track the B-cell maturation axis. CONCLUSIONS: Our data suggest a novel mechanism of drug resistance in which E2a and PRC2 drive changes in the B-cell epigenome; these alterations attenuate alkylating agent treatment-induced apoptosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-016-0305-0) contains supplementary material, which is available to authorized users. BioMed Central 2016-05-04 /pmc/articles/PMC4857420/ /pubmed/27146673 http://dx.doi.org/10.1186/s13073-016-0305-0 Text en © Flinders et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Flinders, Colin Lam, Larry Rubbi, Liudmilla Ferrari, Roberto Fitz-Gibbon, Sorel Chen, Pao-Yang Thompson, Michael Christofk, Heather B Agus, David Ruderman, Daniel Mallick, Parag Pellegrini, Matteo Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma |
title | Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma |
title_full | Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma |
title_fullStr | Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma |
title_full_unstemmed | Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma |
title_short | Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma |
title_sort | epigenetic changes mediated by polycomb repressive complex 2 and e2a are associated with drug resistance in a mouse model of lymphoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857420/ https://www.ncbi.nlm.nih.gov/pubmed/27146673 http://dx.doi.org/10.1186/s13073-016-0305-0 |
work_keys_str_mv | AT flinderscolin epigeneticchangesmediatedbypolycombrepressivecomplex2ande2aareassociatedwithdrugresistanceinamousemodeloflymphoma AT lamlarry epigeneticchangesmediatedbypolycombrepressivecomplex2ande2aareassociatedwithdrugresistanceinamousemodeloflymphoma AT rubbiliudmilla epigeneticchangesmediatedbypolycombrepressivecomplex2ande2aareassociatedwithdrugresistanceinamousemodeloflymphoma AT ferrariroberto epigeneticchangesmediatedbypolycombrepressivecomplex2ande2aareassociatedwithdrugresistanceinamousemodeloflymphoma AT fitzgibbonsorel epigeneticchangesmediatedbypolycombrepressivecomplex2ande2aareassociatedwithdrugresistanceinamousemodeloflymphoma AT chenpaoyang epigeneticchangesmediatedbypolycombrepressivecomplex2ande2aareassociatedwithdrugresistanceinamousemodeloflymphoma AT thompsonmichael epigeneticchangesmediatedbypolycombrepressivecomplex2ande2aareassociatedwithdrugresistanceinamousemodeloflymphoma AT christofkheather epigeneticchangesmediatedbypolycombrepressivecomplex2ande2aareassociatedwithdrugresistanceinamousemodeloflymphoma AT bagusdavid epigeneticchangesmediatedbypolycombrepressivecomplex2ande2aareassociatedwithdrugresistanceinamousemodeloflymphoma AT rudermandaniel epigeneticchangesmediatedbypolycombrepressivecomplex2ande2aareassociatedwithdrugresistanceinamousemodeloflymphoma AT mallickparag epigeneticchangesmediatedbypolycombrepressivecomplex2ande2aareassociatedwithdrugresistanceinamousemodeloflymphoma AT pellegrinimatteo epigeneticchangesmediatedbypolycombrepressivecomplex2ande2aareassociatedwithdrugresistanceinamousemodeloflymphoma |